A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors

Summary

This is an open-label, dose-escalation study of the study drug YH003 . The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH003 in subjects with advanced solid tumors.

Timeline

Start

2021-08-26

Primary completion

2023-03-02

Completion

2023-03-02

Drugs

Indications